Hahn Confirmation Hearing: Pharma May Be Left Parsing Non-Rx Questions For Policy Clues
Executive Summary
US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.
You may also be interested in...
Stephen Hahn Takes US FDA Helm Under Cloud Of Doubt About Vaping Stance
HELP Committee ranking member Patty Murray said because of Hahn's evasive responses to questions about curbing youth e-cigarette use during committee meeeting, she would oppose his confirmation. She also said she was not convinced Hahn would uphold FDA standards.
New US FDA Commissioner Stephen Hahn Heads to White Oak Under Vaping Cloud
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.
Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs
A plurality of the questions from the Senate HELP Committee at Stephen Hahn's confirmation hearing to head the US FDA focused on drug development issues, despite the time lawmakers spent discussing the agency's regulation of e-cigarettes.